Australia's most trusted
source of pharma news
Friday, 29 March 2024
Posted 19 October 2021 AM
AstraZeneca's projected blockbuster breast cancer drug Enhertu has won a provisional green-light from the TGA, with the company now turning its attention to securing subsidised access for Aussie patients.
"This approval marks a significant advance in the treatment of late stage, HER2+ breast cancer, for which there is currently no standard of care in Australia," AstraZeneca said in a company statement.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.